再生元制药

US · REGN #285 按市值排名上市于 1970

790.74 -5.60 -0.70%

实时 - 追踪5344个代码 - 心跳于236秒前 · 2026-10-16 20:02

✦ 量化股权信号计算方式说明

增持

最近一期（2026/Q3）披露持股的机构数量减少了9家。
机构持股总比例上升了0.3个百分点。

机构持股

机构持股比例: 94.20% +0.35pp
机构数量: 1,648 -9
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund78.81%

Hedge Fund4.61%

Public Company4.13%

Individual/Insider3.83%

Government Pension Fund2.56%

Private Company1.85%

Sovereign Wealth Fund1.27%

Insurance Company0.42%

Family Office/Trust0.20%

Other2.34%

主要股东截至 2026-06-30

BlackRock 9.13% · 9.11M 股

Vanguard Capital Management, LLC 7.20% · 7.19M 股

Dodge & Cox 4.88% · 4.87M 股

State Street Global Advisors 4.84% · 4.83M 股

Invesco Capital Management LLC 3.24% · 3.24M 股

Other 70.71%

Vanguard Portfolio Management, LLC 3.18% · 3.18M 股

J.P. Morgan Asset Management, Inc. 3.17% · 3.16M 股

Geode Capital Management, LLC 2.63% · 2.63M 股

Leonard Schleifer 2.42% · 2.41M 股

Putnam LLC 2.31% · 2.31M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 27次买入 · 23次卖出

姓名	职务	持股比例
Leonard Schleifer	Co-Founder, President, CEO & Co-Chairman	2.42%
George Yancopoulos	Co-Founder, President, Chief Scientific Officer & Co-Chairman	1.17%
Andrew Murphy	Executive Vice President of Research	0.05%
Joseph LaRosa	General Counsel	0.05%
Daniel Van Plew	Executive VP and GM of Industrial Operations & Product Supply	0.04%
George Sing	Independent Director	0.03%
Christopher Fenimore	Senior VP, Head of Accounting & Controller	0.02%
Marion McCourt	Executive Vice President of Commercial	0.01%
Michael Brown	Independent Director	0.01%
Robert Landry	Chief Financial Officer	0.01%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-02	Marion McCourt	Executive Vice President of Commercial	Automatic Disposition	-2,346	$850.00–857.39
2026-09-02	Marion McCourt	Executive Vice President of Commercial	Intent to Sell (Form 144)	-1,131	$857.00
2026-09-01	Marion McCourt	Executive Vice President of Commercial	Intent to Sell (Form 144)	-1,215	$850.00
2026-09-01	Kathryn Guarini	Independent Director	Derivative Exercise and Sale	-400	$719.37–850.00
2026-08-18	Joseph LaRosa	General Counsel	Derivative Exercise and Sale	-9,019	$381.92–830.15
2026-08-18	Joseph LaRosa	General Counsel	Derivative Exercise and Retained	+3,263	$381.92
2026-08-17	Christopher Fenimore	Senior VP, Head of Accounting & Controller	Derivative Exercise and Sale	-4,599	$381.92–813.47
2026-08-17	Christopher Fenimore	Senior VP, Head of Accounting & Controller	Derivative Exercise and Retained	+1,684	$381.92
2026-08-09	Huda Zoghbi	Independent Director	Derivative Exercise and Sale	-800	$376.69–800.00
2026-08-09	Kathryn Guarini	Independent Director	Derivative Exercise and Sale	-400	$719.37–800.00
2026-07-01	Arthur Ryan	Independent Director	Automatic Disposition	-200	$650.15
2026-04-30	Arthur Ryan	Independent Director	Open Market Disposition	-100	$701.76–714.13
2026-03-31	Arthur Ryan	Independent Director	Automatic Disposition	-100	$771.32–779.71
2026-03-01	Arthur Ryan	Independent Director	Automatic Disposition	-100	$777.46–789.28
2026-02-18	Huda Zoghbi	Independent Director	Derivative Exercise and Sale	-1,638	$376.69–790.00
2026-02-08	Arthur Ryan	Independent Director	Automatic Disposition	-100	$775.63–787.82
2026-02-08	Jason Pitofsky	Vice President	Automatic Disposition	-1,036	$778.35–785.72
2026-02-08	Jason Pitofsky	Vice President	Derivative Exercise and Sale	-1,000	$492.00–778.35
2026-01-06	Bonnie Bassler	Independent Director	Derivative Exercise and Sale	-1,500	$374.12–800.00
2026-01-01	Christine Poon	Lead Independent Director	Other Acquisition	+155	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:12 · 仅供参考，不构成投资建议，也未考虑您的具体情况。